Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Peer-reviewed publication in the American Journal of Infection Control demonstrates the use of CVCs protected with Arrowg+ard™ Technology are associated with a statistically significant and clinically meaningful reduction in the hazard of CLABSI compared with plain CVCs¹.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30-day period.¹

CLABSI remains among the most serious healthcare-associated infections, increasing patient risk, length of stay and morbidity, and increased healthcare costs.² In this prospective multinational study of 1,750 critically ill patients across six hospitals in four countries, patients receiving CVCs protected with Arrowg+ard™ Technology experienced a 70% lower risk of CLABSI during the 30-day period than patients receiving plain CVCs (HR 0.297; 95% CI 0.134-0.658; p=0.003).¹

"At Teleflex, we are committed to investing in and generating clinical evidence necessary to support informed healthcare decision-making," said Jake Newman, President and General Manager, Global Vascular and Emergency Medicine, Teleflex. "These findings strengthen the clinical evidence supporting Arrowg+ard™ Technology and reinforce our commitment to developing innovations that help clinicians and improve patient outcomes.”

"Preventing healthcare-associated infections remains a critical priority for clinicians and healthcare systems worldwide,” said Dr. Amy Bardin, Vice President, Clinical and Medical Affairs, Teleflex. "Clinicians rely on high-quality clinical evidence to inform infection prevention strategies. This multinational study adds important clinical evidence supporting Arrowg+ard™ Technology and demonstrates a statistically significant association with reduced CLABSI hazard among critically ill patients”.

The recently published study builds upon Teleflex's previously announced 2025 multinational prospective cohort study, which demonstrated a 70.5% reduction in overall CLABSI incidence among patients receiving Arrowg+ard Blue™ or Arrowg+ard Blue Plus™ CVCs compared with plain CVCs.² While the 2025 publication focused on overall CLABSI incidence, the latest analysis evaluated time-to-infection, demonstrating that patients receiving catheters protected with Arrowg+ard™ Technology remained significantly less likely to develop CLABSI throughout the 30-day catheterization period. Together, these complementary studies provide evidence of both reduced overall infection burden and reduction in infection risk over time.

Key Findings from the Study¹

Highlights include:

• CVCs with Arrowg+ard^™ Protection were associated with a 70% lower hazard of CLABSI compared with plain CVCs in the 30-day period (HR=0.297; 95% CI 0.134–0.658; p=0.003).
• No CLABSIs events during 0-5 catheter days among patients receiving CH/SSD CVCs, compared to 13 CLABSIs events in the plain CVC group (p= .026).
• Significant separation of infection-risk curves within 30 days of catheter insertion, demonstrating a reduction in CLABSI risk over time (p= .021).
• Significantly lower mortality in the CH/SSD CVC group than in the plain CVC group (18.4% vs 28.3%; p< .001).
• Protective association observed despite significantly longer catheter dwell times in the CH/SSD CVC group (11.56 vs 7.43 days; p< .001).

The findings were published in the American Journal of Infection Control in the article, "Prospective Multicenter Multinational Cohort Study: Time-to-Central Line-Associated Bloodstream Infection with Plain vs Chlorhexidine/Silver Sulfadiazine Impregnated Central Venous Catheters.¹" The full study findings can be accessed at https://www.sciencedirect.com/science/article/pii/S0196655326005869.

International infection prevention guidelines recommend considering antimicrobial or antiseptic-impregnated CVCs in patients or settings where CLABSI rates remain elevated despite implementation of evidence-based prevention practices.³ These findings provide additional prospective evidence supporting those recommendations and further strengthen the clinical evidence supporting the use of antiseptic-impregnated catheter technology in appropriate patient populations.

About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Reference:

1. Rosenthal VD, Jin Z, Yin R, et al. Prospective multicenter multinational cohort study: Time-to-central line-associated bloodstream infection with plain vs chlorhexidine/silver sulfadiazine impregnated central venous catheters. Am J Infect Control. Published online July 11, 2026. doi:10.1016/j.ajic.2026.07.005. Teleflex funded editorial support but was not involved in data analysis or manuscript content.
2. Rosenthal VD, Yin R, Jin Z, et al. Multicenter, Multinational, Prospective Cohort Study of the Impact of Chlorhexidine Impregnated vs. Plain Central Lines on Central Line-associated Bloodstream Infections. Am J Infect Control. 2025;53(8):862-868. Published online March 6, 2025. doi:https://doi.org/10.1016/j.ajic.2025.03.002 Teleflex funded editorial support but was not involved in data analysis or manuscript content. The Rosenthal et al. study is referenced for only the pre-specified CVC subgroup analysis, which excludes PICCS.
3. Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infection Control & Hospital Epidemiology. 2022;43(5):553-569. Doi:10.1017/ice.2022.87

Rx Only. CAUTION: Federal (USA) law restricts these devices to sale or use by or on the order of a physician.

Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.

Information in this material is not a substitute for the product Instructions for Use. Refer to the package insert provided with the product for complete warnings, indications, contraindications, precautions, potential complications, and instructions for use.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard, Arrowg+ard Blue, Arrowg+ard Blue Plus, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

Not all products may be available in all countries. Please contact your local representative.

© 2026 Teleflex Incorporated. All rights reserved.